Inventor
GUNDE TEA
CH25 patents
⚠️ This page may combine multiple inventors who share the name “GUNDE TEA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
Numab Therapeutics AG
9 patentsUS12077588B2Sep 3, 2024
Antibodies targeting PDL1 and methods of use thereof
Numab Therapeutics AG0 citations57
US11578133B2Feb 14, 2023
Antibodies targeting CD137 and methods of use thereof
Numab Therapeutics AG0 citations57
US11319371B2May 3, 2022
Anti-CD3 antibodies
Numab Therapeutics AG1 citations57
US12202911B2Jan 21, 2025
Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
Numab Therapeutics AG0 citations56
US12209133B2Jan 28, 2025
Antibodies targeting CD137 and methods of use thereof
Numab Therapeutics AG0 citations55
US10774140B2Sep 15, 2020
Anti-TNFα-antibodies and functional fragments thereof
Numab Therapeutics AG0 citations51
US12503505B2Dec 23, 2025
Multispecific antibodies having specificity for TNFα and IL-17A, antibodies targeting IL-17A, and methods of use thereof
Numab Therapeutics AG0 citations50
US12098203B2Sep 24, 2024
Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA
Numab Therapeutics AG0 citations49
US11365240B2Jun 21, 2022
Anti-HSA antibodies
Numab Therapeutics AG0 citations45
ESBATECH ALCON BIOMED RES UNIT
6 patentsUS9090684B2Jul 28, 2015
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT54 citations97
US9422366B2Aug 23, 2016
Stable and soluble antibodies inhibiting TNF alpha
ESBATECH ALCON BIOMED RES UNIT12 citations92
US8349322B2Jan 8, 2013
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT31 citations92
US10590193B2Mar 17, 2020
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT9 citations83
US10100111B2Oct 16, 2018
Stable and soluble antibodies inhibiting TNF alpha
ESBATECH ALCON BIOMED RES UNIT7 citations83
US9873737B2Jan 23, 2018
Stable and soluble antibodies inhibiting VEGF
ESBATECH ALCON BIOMED RES UNIT10 citations83
TILLOTTS PHARMA AG
4 patentsUS11459383B2Oct 4, 2022
Anti-TNF-alpha-antibodies and functional fragments thereof
TILLOTTS PHARMA AG5 citations82
US12209122B2Jan 28, 2025
Anti-TNF-alpha-antibodies and functional fragments thereof
TILLOTTS PHARMA AG0 citations61
US12043663B2Jul 23, 2024
Anti-TNF-alpha-antibodies and functional fragments thereof
TILLOTTS PHARMA AG0 citations61
US10975143B2Apr 13, 2021
Anti-TNF-α-antibodies and functional fragments thereof
TILLOTTS PHARMA AG0 citations61